Overview
Binds to stereospecific benzodiazepine receptors on the postsynaptic GABA neuron at several sites within the central nervous system, including the limbic system, reticular formation. Enhancement of the inhibitory effect of GABA on neuronal excitability results by increased neuronal membrane permeability to chloride ions. This shift in chloride ions results in hyperpolarization (a less excitable state) and stabilization. Benzodiazepine receptors and effects appear to be linked to the GABA-A receptors

Coverage Guidelines
Authorization may be granted for members who are currently receiving treatment with Nayzilam excluding when the product is obtained as samples or via manufacturer’s patient assistance programs. OR
Authorization may be granted for members when all the following criteria are met, and documentation is provided:
1. The member is ≥ 12 years of age
2. The member is using medication for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity (ie, seizure clusters, acute repetitive seizures) that are distinct from a patient’s usual seizure pattern
3. The provider specialty is neurology or provider is working in consultation with a neurologist.

Continuation of Therapy
Reauthorization requires physician documentation of improvement of member’s condition.

Limitations
1. Authorizations will be approved for a duration of 12 months
2. The following quantity limits apply:

<table>
<thead>
<tr>
<th>Quantity Limit</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nayzilam 5mg/0.1mL (2 per box)</td>
</tr>
<tr>
<td>5 boxes (10 units total) per 30 days</td>
</tr>
</tbody>
</table>

**References**


**Review History**

12/16/2019 – reviewed and approved by DCC
03/18/2020 – criteria reviewed at P&T

**Disclaimer**

AllWays Health Partners complies with applicable federal civil rights laws and does not discriminate or exclude people on the basis of race, color, national origin, age, disability, or sex.